Keyphrases
Advanced Hepatocellular Carcinoma
13%
Adverse Events
14%
Amino Acid Supplementation
11%
Atorvastatin
11%
Branched-chain Amino Acids
11%
Cause Analysis
11%
Cell-free DNA (cfDNA)
11%
Cirrhosis
53%
Cirrhotic Patients
17%
Clinical Characteristics
12%
Clinical Trials
13%
Cognitive Function
11%
Complete Response
11%
Dermatological Adverse Effects
11%
Elderly Patients
11%
Fibrolamellar Hepatocellular Carcinoma
11%
Genetic Profile
11%
Hepatic Encephalopathy
38%
Hepatic Tumorigenesis
11%
Hepatitis C Treatment
23%
Hepatitis C Virus
11%
Hepatitis C Virus Subtype
11%
Hepatitis E Infection
11%
Hepatocellular Carcinoma
100%
High-fat Diet
11%
High-resolution
11%
HIV Infection
11%
Lipotoxicity
11%
Liver Transplantation
11%
Magnetic Resonance
11%
Minimal Hepatic Encephalopathy
16%
Multi-cohort Studies
11%
Natural History
11%
Nodule
23%
Non-alcoholic Fatty Liver Disease (NAFLD)
18%
Non-cirrhotic
11%
Ornithine Phenylacetate
11%
Overall Survival
19%
Plasma Ammonia
11%
Pork Meat
11%
Portal Vein Thrombosis
19%
Screening Program
11%
Sorafenib
37%
Spain
24%
Subtype Heterogeneity
11%
Survival Events
11%
Ultra-deep Sequencing
11%
Upper Gastrointestinal Bleeding
11%
White Matter Lesions
23%
White Matter Volume
11%
Medicine and Dentistry
Adverse Event
13%
Brain Disease
6%
Brain Edema
6%
Branched Chain Amino Acid
11%
Carcinogenesis
11%
Cognition
12%
Dermatological Agent
11%
Diseases
5%
Glutamine
11%
Hepatic Encephalopathy
46%
Hepatitis C
11%
Hepatocellular Carcinoma
64%
Hepatology
12%
High Fat Food
11%
Human Immunodeficiency Virus
11%
Human Immunodeficiency Virus Infection
11%
Isoniazid
11%
Lipotoxicity
11%
Liver Cancer
11%
Liver Carcinogenesis
9%
Liver Cirrhosis
36%
Liver Disease
12%
Liver Fibrosis
11%
Liver Transplantation
11%
Magnetic Resonance Imaging
7%
Non-Alcoholic Fatty Liver Disease
16%
Ornithine Phenylacetate
11%
Overall Survival
5%
Portal Vein Thrombosis
11%
Portosystemic Anastomosis
5%
Provocation Test
5%
Screening
11%
Sorafenib
13%
Supplementation
11%
Upper Gastrointestinal Bleeding
11%
White Matter Lesion
23%
